{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Ependymomas&page=8", "query": { "condition": "Ependymomas", "page": 8 }, "page_size": 10 }, "pagination": { "page": 8, "page_size": 10, "total_count": 264, "total_pages": 27, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Ependymomas&page=9&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Ependymomas&page=7&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-27T07:21:24.498Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04284774", "title": "Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Malignant Solid Neoplasm", "Recurrent Adrenal Gland Pheochromocytoma", "Recurrent Ectomesenchymoma", "Recurrent Ependymoma", "Recurrent Ewing Sarcoma", "Recurrent Hepatoblastoma", "Recurrent Kidney Wilms Tumor", "Recurrent Langerhans Cell Histiocytosis", "Recurrent Malignant Germ Cell Tumor", "Recurrent Malignant Glioma", "Recurrent Medulloblastoma", "Recurrent Melanoma", "Recurrent Neuroblastoma", "Recurrent Non-Hodgkin Lymphoma", "Recurrent Osteosarcoma", "Recurrent Peripheral Primitive Neuroectodermal Tumor", "Recurrent Rhabdoid Tumor", "Recurrent Rhabdoid Tumor of the Kidney", "Recurrent Rhabdomyosarcoma", "Recurrent Soft Tissue Sarcoma", "Recurrent Thyroid Gland Carcinoma", "Recurrent WHO Grade 2 Glioma", "Refractory Adrenal Gland Pheochromocytoma", "Refractory Ependymoma", "Refractory Ewing Sarcoma", "Refractory Hepatoblastoma", "Refractory Langerhans Cell Histiocytosis", "Refractory Malignant Germ Cell Tumor", "Refractory Malignant Glioma", "Refractory Medulloblastoma", "Refractory Melanoma", "Refractory Neuroblastoma", "Refractory Non-Hodgkin Lymphoma", "Refractory Osteosarcoma", "Refractory Peripheral Primitive Neuroectodermal Tumor", "Refractory Rhabdoid Tumor", "Refractory Rhabdoid Tumor of the Kidney", "Refractory Rhabdomyosarcoma", "Refractory Soft Tissue Sarcoma", "Refractory Thyroid Gland Carcinoma", "Refractory WHO Grade 2 Glioma" ], "interventions": [ { "name": "Tipifarnib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Months", "maximum_age": "21 Years", "sex": "ALL", "summary": "12 Months to 21 Years" }, "enrollment_count": 5, "start_date": "2020-10-13", "completion_date": "2027-09-30", "has_results": true, "last_update_posted_date": "2026-10-16", "last_synced_at": "2026-10-27T07:21:24.498Z", "location_count": 171, "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 129 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Mesa", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT04284774" }, { "nct_id": "NCT01836549", "title": "Imetelstat Sodium in Treating Younger Patients With Recurrent or Refractory Brain Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Anaplastic Astrocytoma", "Anaplastic Ependymoma", "Astrocytoma, Grade II", "Ependymoma", "Giant Cell Glioblastoma", "Glioblastoma", "Gliosarcoma", "Oligodendroglioma", "Brainstem Tumors" ], "interventions": [ { "name": "imetelstat sodium", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pediatric Brain Tumor Consortium", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Months", "maximum_age": "21 Years", "sex": "ALL", "summary": "12 Months to 21 Years" }, "enrollment_count": 43, "start_date": "2013-03", "completion_date": "2016-04", "has_results": true, "last_update_posted_date": "2018-07-20", "last_synced_at": "2026-10-27T07:21:24.498Z", "location_count": 11, "location_summary": "Los Angeles, California • Palo Alto, California • Washington D.C., District of Columbia + 8 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT01836549" }, { "nct_id": "NCT00520936", "title": "A Study of Pemetrexed in Children With Recurrent Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Osteosarcoma", "Medulloblastoma", "Sarcoma, Ewing's", "Neuroblastoma (Measurable Disease)", "Neuroblastoma (Metaiodobenzylguanidine", "Positive Evaluable)", "Rhabdomyosarcoma", "Ependymoma", "Non-brainstem High-grade Glioma" ], "interventions": [ { "name": "pemetrexed", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "22 Years", "sex": "ALL", "summary": "Up to 22 Years" }, "enrollment_count": 72, "start_date": "2007-09", "completion_date": "2010-02", "has_results": true, "last_update_posted_date": "2011-02-25", "last_synced_at": "2026-10-27T07:21:24.498Z", "location_count": 1, "location_summary": "Arcadia, California", "locations": [ { "city": "Arcadia", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00520936" }, { "nct_id": "NCT04661384", "title": "Brain Tumor-Specific Immune Cells (IL13Ralpha2-CAR T Cells) for the Treatment of Leptomeningeal Glioblastoma, Ependymoma, or Medulloblastoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Ependymoma", "Glioblastoma", "Medulloblastoma", "Recurrent Metastatic Malignant Neoplasm in the Leptomeninges" ], "interventions": [ { "name": "IL13Ralpha2-specific Hinge-optimized 41BB-co-stimulatory CAR Truncated CD19-expressing Autologous T-Lymphocytes", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 10, "start_date": "2021-03-05", "completion_date": "2027-01-12", "has_results": false, "last_update_posted_date": "2026-03-05", "last_synced_at": "2026-10-27T07:21:24.498Z", "location_count": 1, "location_summary": "Duarte, California", "locations": [ { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04661384" }, { "nct_id": "NCT02774421", "title": "Pilot Study of the Effect of Trastuzumab and GM-CSF on Children With Recurrent Ependymoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Posterior Fossa Ependymoma (PFEPN)" ], "interventions": [ { "name": "Trastuzumab after SubQ GM-CSF", "type": "DRUG" }, { "name": "Trastuzumab in combination with SubQ GM-CSF", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Colorado, Denver", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Months", "maximum_age": "21 Years", "sex": "ALL", "summary": "12 Months to 21 Years" }, "enrollment_count": 10, "start_date": "2017-06-12", "completion_date": "2026-03-31", "has_results": false, "last_update_posted_date": "2026-08-31", "last_synced_at": "2026-10-27T07:21:24.498Z", "location_count": 1, "location_summary": "Aurora, Colorado", "locations": [ { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT02774421" }, { "nct_id": "NCT01032070", "title": "Erlotinib Versus Oral Etoposide in Patients With Recurrent or Refractory Pediatric Ependymoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Recurrent or Refractory Pediatric Ependymoma" ], "interventions": [ { "name": "erlotinib", "type": "DRUG" }, { "name": "etoposide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "OSI Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "21 Years", "sex": "ALL", "summary": "1 Year to 21 Years" }, "enrollment_count": 25, "start_date": "2010-09-27", "completion_date": "2012-11-26", "has_results": true, "last_update_posted_date": "2024-12-12", "last_synced_at": "2026-10-27T07:21:24.498Z", "location_count": 18, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Orange, California + 14 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Orange", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT01032070" }, { "nct_id": "NCT01682746", "title": "Photodynamic Therapy (PDT) for Recurrent Pediatric Brain Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Brain Tumor, Recurrent" ], "interventions": [ { "name": "Photofrin (porfimer sodium) & photodynamic therapy.", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Harry T Whelan, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Months", "maximum_age": "18 Years", "sex": "ALL", "summary": "6 Months to 18 Years" }, "enrollment_count": 5, "start_date": "2013-03", "completion_date": "2018-06-29", "has_results": false, "last_update_posted_date": "2019-02-25", "last_synced_at": "2026-10-27T07:21:24.498Z", "location_count": 1, "location_summary": "Wauwatosa, Wisconsin", "locations": [ { "city": "Wauwatosa", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT01682746" }, { "nct_id": "NCT05857969", "title": "Ex Vivo Drug Sensitivity Testing and Multi-Omics Profiling", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Recurrent Childhood Acute Myeloid Leukemia", "Recurrent Childhood Acute Lymphoblastic Leukemia", "Recurrent Childhood Large Cell Lymphoma", "Refractory Childhood Acute Lymphoblastic Leukemia", "Refractory Childhood Hodgkin Lymphoma", "Refractory Childhood Malignant Germ Cell Neoplasm", "Recurrent Childhood Brain Tumor", "Recurrent Childhood Brainstem Glioma", "Recurrent Childhood Rhabdomyosarcoma", "Recurrent Childhood Soft Tissue Sarcoma", "Recurrent Childhood Ependymoma", "Recurrent Childhood Lymphoblastic Lymphoma", "Recurrent Childhood Gliosarcoma", "Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive", "Refractory Childhood Malignant Solid Neoplasm", "Recurrent Childhood Malignant Solid Neoplasm", "Recurrent Childhood Malignant Neoplasm", "Refractory Childhood Malignant Neoplasm" ], "interventions": [ { "name": "Functional Precision Medicine", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Florida International University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Day", "maximum_age": "21 Years", "sex": "ALL", "summary": "1 Day to 21 Years" }, "enrollment_count": 65, "start_date": "2023-02-22", "completion_date": "2028-12-31", "has_results": false, "last_update_posted_date": "2026-08-26", "last_synced_at": "2026-10-27T07:21:24.498Z", "location_count": 1, "location_summary": "Miami, Florida", "locations": [ { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05857969" }, { "nct_id": "NCT02101905", "title": "Lapatinib Ditosylate Before Surgery in Treating Patients With Recurrent High-Grade Glioma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Anaplastic Astrocytoma", "Anaplastic Ependymoma", "Anaplastic Oligodendroglioma", "Gliosarcoma", "Mixed Glioma", "Recurrent Adult Brain Neoplasm", "Recurrent Glioblastoma" ], "interventions": [ { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Lapatinib", "type": "DRUG" }, { "name": "Lapatinib Ditosylate", "type": "DRUG" }, { "name": "Pharmacological Study", "type": "OTHER" }, { "name": "Therapeutic Conventional Surgery", "type": "PROCEDURE" } ], "intervention_types": [ "OTHER", "DRUG", "PROCEDURE" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 29, "start_date": "2016-11-07", "completion_date": "2024-10-30", "has_results": false, "last_update_posted_date": "2024-11-06", "last_synced_at": "2026-10-27T07:21:24.498Z", "location_count": 12, "location_summary": "Los Angeles, California • Baltimore, Maryland • Boston, Massachusetts + 9 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Basking Ridge", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT02101905" }, { "nct_id": "NCT00036959", "title": "ABT-751 in Treating Young Patients With Refractory Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Brain and Central Nervous System Tumors", "Childhood Germ Cell Tumor", "Extragonadal Germ Cell Tumor", "Kidney Cancer", "Liver Cancer", "Neuroblastoma", "Ovarian Cancer", "Sarcoma", "Unspecified Childhood Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "ABT-751", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institutes of Health Clinical Center (CC)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "18 Years", "sex": "ALL", "summary": "Up to 18 Years" }, "enrollment_count": 90, "start_date": "2002-03", "completion_date": "2010-02", "has_results": false, "last_update_posted_date": "2012-03-15", "last_synced_at": "2026-10-27T07:21:24.498Z", "location_count": 3, "location_summary": "Chicago, Illinois • Bethesda, Maryland • Philadelphia, Pennsylvania", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Bethesda", "state": "Maryland" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00036959" } ] }